Citadel Advisors’s KALA BIO KALA Stock Holding History

Citadel Advisors’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8	Closed	-$26K	–	14110
2021 Q4	$26K	Sell	8 -19	-70%	-$88.2K	﹤0.01%	13520
2021 Q3	$177K	Sell	27 -10	-27%	-$86.3K	﹤0.01%	12153
2021 Q2	$493K	Buy	37 +2	+6%	+$31.4K	﹤0.01%	10096
2021 Q1	$582K	Buy	35 +2	+6%	+$39K	﹤0.01%	9351
2020 Q4	$556K	Buy	33 +13	+65%	+$245K	﹤0.01%	7941
2020 Q3	$381K	Hold	20	–	–	﹤0.01%	7750
2020 Q2	$535K	Sell	20 -10	-33%	-$283K	﹤0.01%	6950
2020 Q1	$668K	Buy	30 +12	+67%	+$192K	﹤0.01%	6001
2019 Q4	$165K	Buy	+18	New	+$174K	﹤0.01%	8311
2018 Q4	–	Sell	-6	Closed	-$159K	–	9458
2018 Q3	$159K	Buy	+6	New	+$183K	﹤0.01%	8354
2018 Q2	–	Sell	-5	Closed	-$192K	–	9069
2018 Q1	$192K	Buy	+5	New	+$190K	﹤0.01%	7382

Other funds holding KALA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's KALA Position: Q1 2026 in Review

Citadel Advisors increased its KALA BIO (KALA) stake by 399% in Q1 2026, buying an estimated $95.3K and bringing the position to 5,633 shares worth $48.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12410.

Citadel Advisors first reported a position in KALA in Q4 2018 and has held it in 18 quarters since. The position peaked at $2.18M in Q1 2020. 28 funds tracked by Wall St. Rank hold KALA as of Q1 2026.

Citadel Advisors held 5,633 shares of KALA BIO worth $48.8K as of Q1 2026.
Citadel Advisors bought 4,505 KALA BIO shares in Q1 2026, an estimated $95.3K.
KALA BIO made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12410 holding.
Citadel Advisors first reported a position in KALA BIO in Q4 2018 and has held it in 18 quarters since.
Citadel Advisors's KALA BIO position peaked at $2.18M in Q1 2020.
28 funds tracked by Wall St. Rank held KALA BIO as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.